Altre lingue NRx Pharmaceuticals, Inc.

Azioni

BRPA

US6294442099

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 02/05/2024			Variaz. 5gg	Var. 1 gen.
2,06 ^USD	-5,50%		-34,39%	-55,22%

30/04	NRx Pharmaceuticals, Inc. annuncia risultati promettenti nello studio clinico di Fase 2B/3 di Nrx-101 contro Lurasidone. Lurasidone per il trattamento della depressione bipolare suicida	CI
18/04	Fondi negoziati in borsa, futures azionari in rialzo prima della campanella di giovedì, in vista dei discorsi dei responsabili politici della Fed	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

NRx Pharmaceuticals : Notice of Acceleration - Form 8-K	02/05
NRx Pharmaceuticals Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression	01/05
NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression	30/04
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock	19/04
NRx Pharmaceuticals Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement	19/04
NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq	18/04
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches	18/04
Top Premarket Decliners	18/04
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities; Shares Slump Premarket	18/04
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities, Working Capital	17/04
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics	17/04
NRx Pharmaceuticals Announces Development of New, Proprietary Formulation of HTX-100	16/04
NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)	15/04
NRx Pharmaceuticals Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression	09/04
NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression	08/04
NRx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	02/04
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights	28/03
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing	28/03
UPDATE, NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024	27/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue NRx Pharmaceuticals, Inc.

Azioni

BRPA

US6294442099

Altre lingue

Filtri